InspireMD, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; filed February 16, 2017. Although the request references 2016 Q4, this filing reports annual results, not standalone fourth-quarter financial results.
Business context
InspireMD develops and commercializes stents using its MicroNet embolic-protection mesh. Its principal commercial product is CGuard EPS for carotid artery procedures; MGuard Prime EPS is a bare-metal coronary stent. Products were marketed internationally, principally through distributors. None was approved for sale in the United States. CGuard accounted for 61% of 2016 revenue and MGuard products for 39%.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $1.894 million | $2.310 million |
| Gross profit (loss) | $102,000 | ($296,000) |
| Gross margin | 5.4% | (12.8)% |
| Operating expenses | $7.750 million | $14.189 million |
| Operating loss | ($7.648 million) | ($14.485 million) |
| Net loss | ($8.461 million) | ($15.585 million) |
| Net cash used in operating activities | $7.495 million | $11.596 million |
| Cash and cash equivalents at year-end | $7.516 million | $3.257 million |
Revenue fell 18.0%: MGuard sales declined 53.5% to $747,000, while CGuard sales rose 63.2% to $1.147 million. Management attributed MGuard’s decline largely to market preference for drug-eluting stents. Gross profit improved mainly because inventory write-offs were lower; slow-moving inventory expense was $50,000 in 2016 versus $588,000 in 2015. Research and development expense declined 64.6% to $1.291 million, selling and marketing expense declined 54.1% to $1.459 million, and general and administrative expense declined 21.7% to $5.000 million, reflecting cost reductions and lower compensation and other spending.
Financing activities provided $11.703 million in cash, principally from the July 2016 preferred-stock-and-warrant offering; operating activities consumed $7.495 million. Working capital was positive $3.816 million at year-end, versus a $2.202 million deficit in 2015; the reported current-assets-to-current-liabilities multiple was 1.8. The filing nevertheless states that available resources were expected to fund operations for only up to six months from the filing date, and the auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern.
Debt is secured by substantially all company and subsidiary assets. The balance sheet reports $2.680 million of current loan maturity at December 31, 2016; the filing also reports a loan principal balance of approximately $1.9 million as of January 5, 2017 and approximately $1.5 million as of February 1, 2017. The amended loan was due June 1, 2017, with required monthly principal and interest payments of approximately $380,000.
Material changes and unusual items
- Net loss narrowed by $7.124 million, or 45.7%, mainly from expense reductions, improved gross profit, and lower financial expense; the company remained loss-making and cash-flow negative.
- The July 2016 financing generated approximately $14.6 million gross proceeds through Series B convertible preferred stock and warrants. Preferred stock carries cumulative dividends of 15% annually for five years, payable in cash or common shares at the company’s discretion, and includes anti-dilution provisions without a stated conversion-price floor.
- A 1-for-25 reverse stock split took effect October 7, 2016. Share and per-share figures in the filing are adjusted for the split.
- The 2016 financial statements include a $457,000 cumulative-effect adjustment associated with adopting a share-based compensation accounting standard; the company elected to recognize forfeitures as they occur.
Outlook, risks and contingencies
Management’s focus is to expand CGuard sales through distribution partners and internal sales initiatives, pursue additional international registrations, and seek financing or strategic partners. A smaller 5 French CGuard delivery catheter is conditional on obtaining sufficient financing; management planned to seek CE-mark approval within three quarters of receiving proceeds. A U.S. FDA pre-submission meeting was expected in Q1 2017, but no company product was then authorized for U.S. marketing. Development of NGuard was deferred until at least Q3 2018; MGuard DES development was tabled and PVGuard was not planned for the near future. The filing provides no quantified revenue or earnings guidance.
Principal risks include the going-concern funding gap; continued losses and dependence on external capital; possible dilution and preferred-stock dividend obligations; debt repayment and asset liens; dependence on a single Israeli manufacturing site and key suppliers; regulatory and clinical uncertainty; intense competition; distributor and customer concentration; foreign-exchange exposure; and geopolitical or operational disruption in Israel. Europe generated 85% of 2016 revenue. Two distributors represented 28% and 13% of revenue, respectively.
The company disclosed a prior voluntary MGuard Prime field corrective action, initiated in 2014 over stent-retention concerns; it resumed shipments after a modified securement process and completed relaunch in 2015. Management considered possible future distributor compensation related to the action reasonably possible, ranging from a minimal amount to €1.075 million. Two lawsuits remained contested: Microbanc and Todd Spenla seek approximately $2.2 million plus unspecified equity-related damages; Medpace seeks $1,967,822 plus interest, costs, and fees. Management stated losses in these cases were not probable or estimable. The filing also describes an earlier Argentina employment claim settled for $100,000 including legal fees.
Important facts for investors to verify
- Whether InspireMD secured sufficient financing or strategic support to continue operations beyond the stated six-month runway.
- Actual debt balance, payment status, and any refinancing, maturity extension, or lender enforcement developments; compare the filing’s balance-sheet and later-date principal figures.
- Subsequent CGuard sales growth, margins, distributor performance, and customer concentration, especially given total revenue decline and Europe’s 85% share.
- Progress and cost of U.S. FDA clinical and regulatory plans, and the availability of financing for the smaller-catheter CGuard project.
- Potential dilution and cash or share settlement of the Series B’s 15% cumulative dividends, conversion and anti-dilution terms, and outstanding warrants.
- Developments in the MGuard field-action exposure and the Microbanc and Medpace lawsuits, including any change in estimated loss or reserve.